不可手术非小细胞肺癌随机II期剂量递增试验(PET-boost试验)的急性和晚期毒性结果
PET-boost随机II期试验(NCT01024829)纳入107例II-III期不可手术非小细胞肺癌患者,比较整体原发肿瘤剂量递增与再分布至治疗前FDG高摄取区域的剂量递增,采用≥72 Gy/24次等毒性整合推量,72%接受同步放化疗。急性≥G3毒性41%,晚期≥G3毒性25%,毒性在预设终止规则范围内。
要点
- 急性≥G3毒性发生率41%,晚期≥G3毒性发生率25%。
- 同步放化疗组急性≥G3吞咽困难14.3%,序贯或单纯放疗组3.3%。
- 17例死亡中13例不能排除与治疗相关,其中10例记录疾病进展。
核心结论
- 个体化剂量递增在不可手术非小细胞肺癌患者中导致急性和晚期毒性高于常规放化疗,但毒性在预设终止规则范围内。
研究设计与样本
- 随机II期试验(NCT01024829)纳入107例II-III期不可手术非小细胞肺癌患者,随机接受整体原发肿瘤或治疗前FDG高摄取区域的剂量递增。
- 患者接受≥72 Gy/24次的等毒性整合推量,可联合或不联合化疗,并设严格剂量限制;毒性按CTCAEv3.0评分至死亡。
主要发现
- 77例(72%)患者接受同步放化疗。
- 急性≥G3毒性发生率为41%,晚期≥G3毒性发生率为25%。
- 同步放化疗组与序贯或单纯放疗组最常见的急性≥G3毒性分别为:吞咽困难14.3% vs 3.3%,呼吸困难2.6% vs 6.7%,肺炎0% vs 6.7%,心脏毒性6.5% vs 3.3%。
- 17例患者死亡,其中13例不能排除与治疗相关;这13例中10例记录疾病进展。
- 9例患者观察到致死性肺出血和食管瘘。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND PURPOSE: The PET-boost randomized phase II trial (NCT01024829) investigated dose-escalation to the entire primary tumour or redistributed to regions of high pre-treatment FDG-uptake in inoperable non-small cell lung cancer (NSCLC) patients. We present a toxicity analysis of the 107 patients randomized in the study. MATERIALS AND METHODS: Patients with stage II-III NSCLC were treated with an isotoxic integrated boost of ≥72 Gy in 24 fractions, with/without chemotherapy and strict dose limits. Toxicity was scored until death according to the CTCAEv3.0. RESULTS: 77 (72%) patients were treated with concurrent chemoradiotherapy. Acute and late ≥G3 occurred in 41% and 25%. For concurrent (C) and sequential or radiotherapy alone (S), the most common acute ≥G3 toxicities were: dysphagia in 14.3% (C) and 3.3% (S), dyspnoea in 2.6% (C) and 6.7% (S), pneumonitis in 0% (C) and 6.7% (S), cardiac toxicity in 6.5% (C) and 3.3% (S). Seventeen patients died of which in 13 patients a possible relation to treatment could not be excluded. In 10 of these 13 patients progressive disease was scored. Fatal pulmonary haemorrhages and oesophageal fistulae were observed in 9 patients. CONCLUSION: Personalized dose-escalation in inoperable NSCLC patients results in higher acute and late toxicity compared to conventional chemoradiotherapy. The toxicity, however, was within the boundaries of the pre-defined stopping rules.
引用
- van Diessen J, De Ruysscher D, Sonke JJ, et al. The acute and late toxicity results of a randomized phase II dose-escalation trial in non-small cell lung cancer (PET-boost trial). Radiother Oncol. 2018. PMID: 30327236. doi:10.1016/j.radonc.2018.09.019
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。